NO20084082L - Antistoffer mot insulin-like vekstfaktor 1 reseptorer og deres anvendelse - Google Patents

Antistoffer mot insulin-like vekstfaktor 1 reseptorer og deres anvendelse

Info

Publication number
NO20084082L
NO20084082L NO20084082A NO20084082A NO20084082L NO 20084082 L NO20084082 L NO 20084082L NO 20084082 A NO20084082 A NO 20084082A NO 20084082 A NO20084082 A NO 20084082A NO 20084082 L NO20084082 L NO 20084082L
Authority
NO
Norway
Prior art keywords
insulin
receptors
antibodies
growth factor
amount
Prior art date
Application number
NO20084082A
Other languages
English (en)
Norwegian (no)
Inventor
Ralf Schumacher
Klaus-Peter Kuenkele
Silke Hansen
Dietmar Reusch
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36940705&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20084082(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NO20084082L publication Critical patent/NO20084082L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20084082A 2006-04-11 2008-09-25 Antistoffer mot insulin-like vekstfaktor 1 reseptorer og deres anvendelse NO20084082L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06007571 2006-04-11
PCT/EP2007/003165 WO2007115814A2 (fr) 2006-04-11 2007-04-10 Anticorps dirigés contre le récepteur du facteur i de croissance analogue à l'insuline et leurs utilisations

Publications (1)

Publication Number Publication Date
NO20084082L true NO20084082L (no) 2008-11-06

Family

ID=36940705

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20084082A NO20084082L (no) 2006-04-11 2008-09-25 Antistoffer mot insulin-like vekstfaktor 1 reseptorer og deres anvendelse

Country Status (20)

Country Link
US (1) US20080014203A1 (fr)
EP (2) EP2007810B1 (fr)
JP (1) JP4718634B2 (fr)
KR (2) KR20120028396A (fr)
CN (1) CN101421305B (fr)
AR (1) AR060592A1 (fr)
AU (1) AU2007236199B2 (fr)
BR (1) BRPI0710185B8 (fr)
CA (2) CA2647181C (fr)
CR (1) CR10301A (fr)
EC (1) ECSP088816A (fr)
ES (1) ES2403075T3 (fr)
IL (1) IL194397A (fr)
MX (1) MX2008012950A (fr)
NO (1) NO20084082L (fr)
NZ (1) NZ571414A (fr)
RU (1) RU2541765C2 (fr)
UA (1) UA95284C2 (fr)
WO (1) WO2007115814A2 (fr)
ZA (1) ZA200808597B (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7846724B2 (en) 2006-04-11 2010-12-07 Hoffmann-La Roche Inc. Method for selecting CHO cell for production of glycosylated antibodies
WO2008079849A2 (fr) * 2006-12-22 2008-07-03 Genentech, Inc. Anticorps liés au récepteur du facteur de croissance semblable à l'insuline
PE20090368A1 (es) 2007-06-19 2009-04-28 Boehringer Ingelheim Int Anticuerpos anti-igf
WO2009080278A1 (fr) 2007-12-21 2009-07-02 F. Hoffmann-La Roche Ag Essai de stabilité d'anticorps
EA029178B1 (ru) 2008-12-12 2018-02-28 Бёрингер Ингельхайм Интернациональ Гмбх Антитела против инсулиноподобных факторов роста, молекула днк, вектор, клетка-хозяин, предназначенные для получения этого антитела, способ его получения и применение
WO2010112194A1 (fr) * 2009-04-02 2010-10-07 F. Hoffmann-La Roche Ag Polypeptides se liant à un antigène et anticorps multispécifiques les renfermant
US20100316639A1 (en) 2009-06-16 2010-12-16 Genentech, Inc. Biomarkers for igf-1r inhibitor therapy
ES2478294T3 (es) 2009-07-24 2014-07-21 F. Hoffmann-La Roche Ag Sistema de agitador
EP2486055A4 (fr) * 2009-10-07 2013-04-17 Us Health Anticorps à domaine humain dirigés contre des composants du système de facteur de croissance de type insuline (igf) humain
DK2493922T3 (en) 2009-10-26 2017-04-24 Hoffmann La Roche Process for preparing a glycosylated immunoglobulin
WO2011101328A2 (fr) 2010-02-18 2011-08-25 Roche Glycart Ag Traitement au moyen d'un anticorps anti-egfr de la classe igg humanisé et d'un anticorps contre le récepteur du facteur de croissance 1 analogue à l'insuline
WO2011135040A1 (fr) 2010-04-30 2011-11-03 F. Hoffmann-La Roche Ag Protéine de fusion d'anticorps fluorescent, sa production et son utilisation
CA2815282C (fr) 2010-11-05 2019-05-21 F. Hoffmann-La Roche Ag Procede optimise pour la capture d'anticorps par une chromatographie en mode mixte
WO2012175508A1 (fr) 2011-06-22 2012-12-27 F. Hoffmann-La Roche Ag Élimination de cellules cibles par des cellules t cytotoxiques circulantes spécifiques du virus à l'aide de complexes comprenant des molécules du cmh de classe i
RU2502798C2 (ru) * 2012-02-22 2013-12-27 Общество с ограниченной ответственностью "Фармако Биотех" КЛЕТОЧНАЯ ЛИНИЯ huFSHIK, СЕКРЕТИРУЮЩАЯ РЕКОМБИНАНТНЫЙ ЧЕЛОВЕЧЕСКИЙ ФСГ
EP2727941A1 (fr) 2012-11-05 2014-05-07 MAB Discovery GmbH Procédé pour la production d'anticorps multispécifiques
WO2014067642A1 (fr) 2012-11-05 2014-05-08 Mab Discovery Gmbh Procédé de fabrication d'anticorps plurispécifiques
MX361076B (es) 2012-12-21 2018-11-27 Hoffmann La Roche Proteínas multifunción que comprenden complejo mayor de histocompatibilidad (cmh) de clase i multivalente unido mediante disulfuro.
US20140255413A1 (en) 2013-03-07 2014-09-11 Boehringer Ingelheim International Gmbh Combination therapy for neoplasia treatment
AR120719A1 (es) * 2019-12-10 2022-03-09 Horizon Therapeutics Ireland Designated Activity Company Anticuerpos glicosilados contra el receptor del factor de crecimiento i similar a la insulina y sus usos

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4675187A (en) 1983-05-16 1987-06-23 Bristol-Myers Company BBM-1675, a new antibiotic complex
US5202238A (en) * 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5204244A (en) * 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5770429A (en) * 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
GB9022543D0 (en) * 1990-10-17 1990-11-28 Wellcome Found Antibody production
US5650508A (en) * 1991-12-27 1997-07-22 Georgia Tech Research Corporation Peptide ketoamides
CA2149329C (fr) 1992-11-13 2008-07-15 Darrell R. Anderson Utilisation d'anticorps hybrides et radioisotopiques diriges contre l'antigene de restriction de la differenciation des lymphocytes b humains pour le traitement du lymphome b
EP2270150B2 (fr) * 1999-04-09 2019-08-07 Kyowa Hakko Kirin Co., Ltd. Methode de regulation de l'activite d'une molecule immunologiquement fonctionnelle
US20030165502A1 (en) * 2000-06-13 2003-09-04 City Of Hope Single-chain antibodies against human insulin-like growth factor I receptor: expression, purification, and effect on tumor growth
US7553485B2 (en) * 2002-01-18 2009-06-30 Pierre Fabre Medicament Anti-IGF-IR and/or anti-insulin/IGF-I hybrid receptors antibodies and uses thereof
US7241444B2 (en) * 2002-01-18 2007-07-10 Pierre Fabre Medicament Anti-IGF-IR antibodies and uses thereof
EP2316922B1 (fr) * 2002-05-24 2013-05-22 Merck Sharp & Dohme Corp. Anticorps anti-IGFR humain neutralisant
ATE549359T1 (de) * 2003-04-02 2012-03-15 Hoffmann La Roche Antikörper gegen den insulinähnlichen wachstumsfaktor i-rezeptor und deren verwendungen
AR046071A1 (es) * 2003-07-10 2005-11-23 Hoffmann La Roche Anticuerpos contra el receptor i del factor de crecimiento de tipo insulinico y los usos de los mismos
US20070142627A1 (en) * 2003-08-01 2007-06-21 Chugai Seiyaku Kabushiki Kaisha Sugar-chain-altered anti-hm1.24 antibody
US8603481B2 (en) * 2003-10-10 2013-12-10 Chugai Seiyaku Kabushiki Kaisha Therapeutic agents for solid tumors

Also Published As

Publication number Publication date
ES2403075T3 (es) 2013-05-13
CA2647181C (fr) 2020-08-11
CN101421305A (zh) 2009-04-29
IL194397A0 (en) 2011-08-01
BRPI0710185B1 (pt) 2020-01-14
KR20080113233A (ko) 2008-12-29
BRPI0710185A2 (pt) 2011-08-09
EP2363417A1 (fr) 2011-09-07
AU2007236199B2 (en) 2013-07-25
BRPI0710185B8 (pt) 2021-05-25
ECSP088816A (es) 2008-11-27
CR10301A (es) 2008-10-29
WO2007115814A2 (fr) 2007-10-18
US20080014203A1 (en) 2008-01-17
NZ571414A (en) 2011-12-22
IL194397A (en) 2014-04-30
JP2009533367A (ja) 2009-09-17
WO2007115814A3 (fr) 2008-01-10
CA3081707A1 (fr) 2007-10-18
EP2007810A2 (fr) 2008-12-31
AR060592A1 (es) 2008-07-02
RU2008144290A (ru) 2010-05-20
CN101421305B (zh) 2013-05-15
AU2007236199A1 (en) 2007-10-18
JP4718634B2 (ja) 2011-07-06
ZA200808597B (en) 2009-11-25
CA2647181A1 (fr) 2007-10-18
BRPI0710185A8 (pt) 2019-01-22
MX2008012950A (es) 2008-10-15
KR101276513B1 (ko) 2013-06-21
UA95284C2 (ru) 2011-07-25
KR20120028396A (ko) 2012-03-22
EP2007810B1 (fr) 2013-02-13
RU2541765C2 (ru) 2015-02-20

Similar Documents

Publication Publication Date Title
NO20084082L (no) Antistoffer mot insulin-like vekstfaktor 1 reseptorer og deres anvendelse
NO20083948L (no) Glykosylerte antistoffer
TW200833712A (en) Antibodies against insulin-like growth factor I receptor and uses thereof
WO2008134724A3 (fr) Procédés d'administration d'anticorps anti-il-5
WO2004087756A3 (fr) Anticorps contre le recepteur du facteur de croissance 1 analogue a l'insuline et utilisations de ceux-ci
WO2005003175A3 (fr) Anticorps d'aglycosyle anti-cd154 (ligand cd40) et utilisations correspondantes
HRP20192295T1 (hr) Optimizirana monoklonska protutijela protiv inhibitora faktora tkivnog puta (tfpi)
WO2009048537A3 (fr) Anticorps humanisé
EP2368913A3 (fr) Anticorps glyco-modifiés
MX2010002716A (es) Uso de slit, nefrina, efrina o semaforina para el tratamiento de enfermedades de cartilago.
BRPI0614040B8 (pt) anticorpo isolado que se liga especificamente a b7rp1, polipeptídeo, composição farmacêutica, vetor de expressão, célula hospedeira, linhagem celular isolada e métodos para a detecção de b7rp1 em uma amostra biológica e de produção de um anticorpo ou polipeptídeo
WO2008036341A3 (fr) Compositions et procédés concernant des anticorps de récepteur du glucagon
BRPI0415195A (pt) anticorpos completamente humanos contra 4-1bb humana (cd137)
UA105768C2 (uk) Антитіла до рецептора кінцевих продуктів глибокого глікування (rage) і їх застосування
RS53752B1 (en) ANTITELO PROTIV ILT7
WO2005120557A3 (fr) Inhibition du recepteur proteique stimulant les macrophages (ron)
BRPI0719762A2 (pt) Anticorpo, composição farmacêutica, polipeptídeo, polinucleotídeo isolado, plasmídeo, célula isolada, e, métodos para fabricar um polipeptídeo que se liga especificamente ao receptor il-17 a, para tratar um estado de doença associado com a ativação de il-17ra em um paciente, para inibir a produção de pelo menos uma citocina, quimiocina, metaloproteinase de matriz ou contra molécula associada com a ativação de il-17ra e para tratar inflamação e doneça autoimune em um paciente.
DOP2009000140A (es) Anticuerpos humanos contra el ligando 4 de tipo delta humano
SG10201407388XA (en) Humanized anti-cxcr5 antibodies, derivatives thereof and their uses
WO2006106348A3 (fr) Glycosylation de proteines
CL2007003825A1 (es) Composicion farmaceutica que comprende un anticuerpo monoclonal humanizado anti-antigeno de diferenciacion leucocitario humano cd6; y su uso para el diagnostico y tratamiento de la leucemia linfocitaria cronica b.
EP2463303A3 (fr) Anticorps monoclonaux pour neutraliser la toxine d'anthrax
TH95354A (th) แอนตี้บอดีต่อโกรท แฟคเตอร์-1 รีเซปเตอร์คล้ายอินซูลิน และการใช้สารนั้น
TH95354B (th) แอนตี้บอดีต่อโกรท แฟคเตอร์-1 รีเซปเตอร์คล้ายอินซูลิน และการใช้สารนั้น
TH96999A (th) แอนตี้บอดี้ที่ถูกไกลโคซิเลท

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: RIVER VISION DEVELOPMENT CORP, US

FC2A Withdrawal, rejection or dismissal of laid open patent application